1 citations
,
November 2018 in “Therapeutic Delivery” New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
January 2025 in “International Journal of Pharmacology” Both steroids, especially cyproterone acetate, harm quail's vital organs.
51 citations
,
August 2021 in “Turkish Journal of Medical Sciences” As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.
December 2025 in “Frontiers in Nutrition” The albumin change rate helps predict treatment success in AIDS-related non-Hodgkin lymphoma.
20 citations
,
November 2017 in “JAAD case reports” Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
May 2026 in “Drug Delivery and Translational Research” The study investigates dual-drug nanostructured lipid carriers containing spironolactone and 2-deoxy-D-ribose for targeted delivery to hair follicles in treating androgenetic alopecia. This approach aims to enhance treatment efficacy by improving drug delivery directly to affected areas, highlighting the potential of nanocarrier-based systems to provide a more effective solution for hair loss. Specific details on study size or outcomes are not provided.
5 citations
,
November 2015 in “Journal of Enzyme Inhibition and Medicinal Chemistry” Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.
8 citations
,
April 1990 in “Hormone and Metabolic Research” The medication combination did not affect glucose tolerance but increased some cholesterol levels due to its estrogen component.
December 2022 in “Plastic and Reconstructive Surgery” PRPF is a safer and more effective treatment for hair loss than PRP.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
January 2024 in “Journal of Cosmetics, Dermatological Sciences and Applications” Injecting a peptide-hyaluronic acid mix improved hair growth in men with hair loss and was safe.
37 citations
,
August 2022 in “Frontiers in pharmacology” Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.
January 2023 in “Applied sciences” Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
2 citations
,
December 1994 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” The treatment effectively reduced hair growth and was safe for patients with PCOS, but it needs better bleeding control.
2 citations
,
July 2022 in “The Kaohsiung Journal of Medical Sciences” FTY720 helps transplanted fat survive better by reducing immune rejection and improving blood vessel growth.
12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
21 citations
,
March 2002 in “PubMed” High-dose steroid pulse therapy effectively regrows hair in severe multifocal alopecia areata.
4 citations
,
January 2020 in “PubMed” JAK inhibitors may become the first approved treatment for alopecia areata if they are proven safe and effective.
1 citations
,
June 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
September 2025 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib effectively promotes hair regrowth and improves well-being in severe alopecia areata patients.
1 citations
,
May 2025 in “Frontiers in Medicine” Dual-targeted therapy is effective and safe for difficult-to-treat inflammatory bowel disease.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
19 citations
,
March 1994 in “Fertility and sterility” The combination therapy reduced hirsutism in women with PCOD and was well-tolerated.
16 citations
,
July 2018 in “Dermatologic Surgery” iL-PRF treatment improves hair growth for androgenetic alopecia.
May 2024 in “Drugs & Therapy Perspectives” New treatments like JAK inhibitors offer hope for better alopecia areata management.
November 2023 in “Journal of Cosmetic Dermatology” Tofacitinib is effective and has minor, reversible side effects for treating severe hair loss in Iran.
5 citations
,
March 2010 in “Gynecologic and obstetric investigation” Cyproterone acetate implants were more effective at reducing facial hair and improving skin in severe hirsutism than oral treatment.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
October 2021 in “Meditsinskiy sovet = Medical Council” Cyproterone acetate improves skin symptoms and quality of life in women with androgen-related issues.